The Pharmaceutical Research Center (PRC) (previously named Investigational Drug Services/IDS) ensures the safe and ethical provision of investigational/study drugs to research subjects enrolled in clinical drug trials within the UWCCC. It ensures that drug research protocols proceed optimally through the University of Wisconsin Hospital and Clinics'(UWHC) medication use system and in accordance with all federal, state, institutional and sponsor regulations: The services are continually refined and expanded to meet the evolving needs of the UWCCC clinical research. While the PRC program at UW/UWHC supports all investigators conducting clinical drug research, its relationship with the UWCCC is unique in its level of commitment, the breadth and depth of services provided, and expertise in handling biohazardous and gene therapy products. The PRC provides detailed protocol review and feasibility assessment within the confines of an academic medical center. It ensures full compliance with federal, state, sponsor and institutional requirements through activities such as: establishment of drug handlihg/distribution/preparation/destruction procedures;creation of investigational drug monographs for health care providers;education of health care staff regarding protocol procedures;creation of preprinted physician orders and prescriptions;drug inventory management and accountability;drug preparation and/or oversight;quality assurance audits;and protocol amendment management. It operates satellite pharmacy locations, optimizing ability to extend clinical research into the community.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Wisconsin Madison
United States
Zip Code
Zahm, Christopher D; Colluru, Viswa T; McIlwain, Sean J et al. (2018) TLR Stimulation during T-cell Activation Lowers PD-1 Expression on CD8+ T Cells. Cancer Immunol Res 6:1364-1374
Chen, Feng; Goel, Shreya; Shi, Sixiang et al. (2018) General synthesis of silica-based yolk/shell hybrid nanomaterials and in vivo tumor vasculature targeting. Nano Res 11:4890-4904
Erbe, Amy K; Wang, Wei; Carmichael, Lakeesha et al. (2018) Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group. Clin Cancer Res 24:189-196
Eckers, Jaimee C; Swick, Adam D; Kimple, Randall J (2018) Identity Crisis - Rigor and Reproducibility in Human Cell Lines. Radiat Res 189:551-552
O'Driscoll, Chelsea A; Owens, Leah A; Gallo, Madeline E et al. (2018) Differential effects of diesel exhaust particles on T cell differentiation and autoimmune disease. Part Fibre Toxicol 15:35
Fleszar, Andrew J; Walker, Alyssa; Porubsky, Veronica et al. (2018) The Extracellular Matrix of Ovarian Cortical Inclusion Cysts Modulates Invasion of Fallopian Tube Epithelial Cells. APL Bioeng 2:
Tucholka, Jennifer L; Yang, Dou-Yan; Bruce, Jordan G et al. (2018) A Randomized Controlled Trial Evaluating the Impact of Web-Based Information on Breast Cancer Patients' Knowledge of Surgical Treatment Options. J Am Coll Surg 226:126-133
Schwei, Rebecca J; Schroeder, Michelle; Ejebe, Ifna et al. (2018) Limited English Proficient Patients' Perceptions of when Interpreters are Needed and how the Decision to Utilize Interpreters is Made. Health Commun 33:1503-1508
Nyman, Patrick E; Buehler, Darya; Lambert, Paul F (2018) Loss of Function of Canonical Notch Signaling Drives Head and Neck Carcinogenesis. Clin Cancer Res 24:6308-6318
Barault, Ludovic; Amatu, Alessio; Siravegna, Giulia et al. (2018) Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer. Gut 67:1995-2005

Showing the most recent 10 out of 1528 publications